Chikungunya virus time course infection of human macrophages reveals intracellular signaling pathways relevant to repurposed therapeutics
© 2022 Gray et al..
Background: Chikungunya virus (CHIKV) is a mosquito-borne pathogen, within the Alphavirus genus of the Togaviridae family, that causes ~1.1 million human infections annually. CHIKV uses Aedes albopictus and Aedes aegypti mosquitoes as insect vectors. Human infections can develop arthralgia and myalgia, which results in debilitating pain for weeks, months, and even years after acute infection. No therapeutic treatments or vaccines currently exist for many alphaviruses, including CHIKV. Targeting the phagocytosis of CHIKV by macrophages after mosquito transmission plays an important role in early productive viral infection in humans, and could reduce viral replication and/or symptoms.
Methods: To better characterize the transcriptional response of macrophages during early infection, we generated RNA-sequencing data from a CHIKV-infected human macrophage cell line at eight or 24 hours post-infection (hpi), together with mock-infected controls. We then calculated differential gene expression, enriched functional annotations, modulated intracellular signaling pathways, and predicted therapeutic drugs from these sequencing data.
Results: We observed 234 pathways were significantly affected 24 hpi, resulting in six potential pharmaceutical treatments to modulate the affected pathways. A subset of significant pathways at 24 hpi includes AGE-RAGE, Fc epsilon RI, Chronic myeloid leukemia, Fc gamma R-mediated phagocytosis, and Ras signaling. We found that the MAPK1 and MAPK3 proteins are shared among this subset of pathways and that Telmisartan and Dasatinib are strong candidates for repurposed small molecule therapeutics that target human processes. The results of our analysis can be further characterized in the wet lab to contribute to the development of host-based prophylactics and therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
PeerJ - 10(2022) vom: 01., Seite e13090 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gray, Madison [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chikungunya virus |
|---|
| Anmerkungen: |
Date Completed 11.01.2023 Date Revised 11.01.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.7717/peerj.13090 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338712380 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338712380 | ||
| 003 | DE-627 | ||
| 005 | 20231226001300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7717/peerj.13090 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338712380 | ||
| 035 | |a (NLM)35341048 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gray, Madison |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chikungunya virus time course infection of human macrophages reveals intracellular signaling pathways relevant to repurposed therapeutics |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2023 | ||
| 500 | |a Date Revised 11.01.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Gray et al. | ||
| 520 | |a Background: Chikungunya virus (CHIKV) is a mosquito-borne pathogen, within the Alphavirus genus of the Togaviridae family, that causes ~1.1 million human infections annually. CHIKV uses Aedes albopictus and Aedes aegypti mosquitoes as insect vectors. Human infections can develop arthralgia and myalgia, which results in debilitating pain for weeks, months, and even years after acute infection. No therapeutic treatments or vaccines currently exist for many alphaviruses, including CHIKV. Targeting the phagocytosis of CHIKV by macrophages after mosquito transmission plays an important role in early productive viral infection in humans, and could reduce viral replication and/or symptoms | ||
| 520 | |a Methods: To better characterize the transcriptional response of macrophages during early infection, we generated RNA-sequencing data from a CHIKV-infected human macrophage cell line at eight or 24 hours post-infection (hpi), together with mock-infected controls. We then calculated differential gene expression, enriched functional annotations, modulated intracellular signaling pathways, and predicted therapeutic drugs from these sequencing data | ||
| 520 | |a Results: We observed 234 pathways were significantly affected 24 hpi, resulting in six potential pharmaceutical treatments to modulate the affected pathways. A subset of significant pathways at 24 hpi includes AGE-RAGE, Fc epsilon RI, Chronic myeloid leukemia, Fc gamma R-mediated phagocytosis, and Ras signaling. We found that the MAPK1 and MAPK3 proteins are shared among this subset of pathways and that Telmisartan and Dasatinib are strong candidates for repurposed small molecule therapeutics that target human processes. The results of our analysis can be further characterized in the wet lab to contribute to the development of host-based prophylactics and therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Chikungunya virus | |
| 650 | 4 | |a Drug repurposing | |
| 650 | 4 | |a Macrophage | |
| 650 | 4 | |a Signaling pathways | |
| 650 | 4 | |a Transcriptomics | |
| 650 | 4 | |a Virology | |
| 700 | 1 | |a Guerrero-Arguero, Israel |e verfasserin |4 aut | |
| 700 | 1 | |a Solis-Leal, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Robison, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Berges, Bradford K |e verfasserin |4 aut | |
| 700 | 1 | |a Pickett, Brett E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PeerJ |d 2013 |g 10(2022) vom: 01., Seite e13090 |w (DE-627)NLM227171578 |x 2167-8359 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g day:01 |g pages:e13090 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7717/peerj.13090 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |b 01 |h e13090 | ||